Rotator Cuff Tears
Conditions
Brief summary
Increasing the success rate of rotator cuff healing remains a tremendous challenge for orthopedic surgeons, which encourage the development of new biological therapies. Among many approaches, activating resident progenitor cells with the Lipogems® product could be an easy, safe, practical and cost-effective new therapeutic strategy for increasing rotator cuff tendon healing. The primary goal of this study is to evaluate efficacy of infiltration of autologous micro-fragmented adipose tissue in arthroscopic rotator cuff repair, in terms of gain in post-operative Constant score.
Detailed description
Increasing the success rate of rotator cuff healing remains a tremendous challenge for orthopedic surgeons, which encourage the development of new biological therapies. Among many approaches, the possibility of activating resident stem cells in situ, without the need of isolating them from biopsies and successive in vitro culturing, could represent a very promising therapeutic strategy. Along this line, it has been recently demonstrated that a lipoaspirate product, such as the Lipogems® product, contains and produces growth factors that may activate resident stem cells. Recently, it has been discovered that also the human rotator cuff contains a reservoir of progenitor cells, which can be isolated and expanded in vitro. The primary goal of this study is to evaluate efficacy of infiltration of autologous micro-fragmented adipose tissue in arthroscopic rotator cuff repair, in terms of gain in post-operative Constant score. Secondary goals are to evaluate efficacy of infiltration of autologous micro-fragmented adipose tissue in arthroscopic rotator cuff repairs, in terms of post-operative pain reduction, gain in post-operative strength in abduction and external rotation; estimate incidence of re-ruptures at 1 and 2 years post-operatively, quantify the amount of fatty degeneration of the supraspinatus at 1 and 2 years post-operatively.
Interventions
PROCEDUREarthroscopic rotator cuff repair
arthroscopic rotator cuff repair
injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
Sponsors
University of Milan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18\< Age \< 75 years. * a full-thickness tear of the supraspinatus and/or infraspinatus tendons (classified according to Snyder as degree C1, C2, C3). * Indication for arthroscopic rotator cuff repair. * Patients able to understand the study conditions and willing to participate for its entire duration. * Patients who signed written informed consent.
Exclusion criteria
* Patients diagnosed with partial supraspinatus/infraspinatus tears (A1, A2, A3, A4, B1, B2, B3, B4 in Snyder classification system). * Patients diagnosed with massive rotator cuff tears C4 in Snyder classification system). * Patients diagnosed with subscapularis tears, of grade III, IV or V in Lafosse classification. * Patients diagnosed with anterior, posterior or multidirectional shoulder instability. * Patients diagnosed with Superior Labrum Anterior-to-Posterior (SLAP)-type long-head of the biceps tendon lesions. * Patients presenting serious comorbidities, which represent contraindications to shoulder arthroscopy. * Patients treated with hyaluronic acid or steroid intra-articular injections in the index shoulder less than 3 months before the procedure. * Patients diagnosed with local (shoulder, site of fat tissue harvest or nearby tissues) or systemic infections, osteomyelitis, sepsis. * Fatty degeneration/atrophy grade III or IV (Goutallier or Fuchs classification) in supraspinatus or infraspinatus muscle bellies. * Patients diagnosed with diabetes * Patients diagnosed with chronic kidney disease with Glomerular Filtration Rate (GFR) less than 60 mL/min. * Patients diagnosed with any disease of coagulation or platelet aggregation systems, or treated with oral anti-coagulating or anti-aggregating agents for which no suspension is possible at the moment of intervention. * Patients chronically treated with immune-suppressants agents. * Patients affected by chronic heart failure. * Patients diagnosed with acute coronary or cerebrovascular disease in the last 6 months. * Patients who reported weight loss greater than 30 kg for any reasons in the last 12 months or, if the cause is unknown, greater than 10 kg in the last 12 months if the cause * Patients diagnosed with eating disorders or body dysmorphic disorders. * Patients with untreated hypo- or hyperthyroidism. * Patients with varicose veins, phlebitis or scars near the fat tissue harvest area. * Drug-addicted, alcohol-addicted patients, patients with psychiatric disorders or other clinical conditions, which could compromise the results of the surgical procedure or of the follow-up. * Informed consent not accepted. * Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Constant score between the two groups at 6 months post-operatively | 6 months | Hypothesis: in the treatment group, Constant score at 6 months post-operatively is at least 7 points HIGHER than Constant score in the control group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of ASES score between the two groups at 1, 3, 6, 12, 18, 24 months post-operatively | 1, 3, 6, 12, 18, 24 months | — |
| Comparison of Visual Analogue Scale (VAS) difference between the two groups at 1, 3, 7, 14, 30 days and 3, 6, 12, 18, 24 months post-operatively. | 1, 3, 7, 14, 30 days and 3, 6, 12, 18, 24 months | — |
| Comparison SST score (simple shoulder test) between the two groups at 1, 3, 6, 12, 18, 24 months post-operatively. | 1, 3, 6, 12, 18, 24 months | — |
| Comparison of Constant score between the two groups at 1, 3, 6, 12, 18, 24 months post-operatively | 1, 3, 6, 12, 18, 24 months | — |
| Comparison of incidence of re-ruptures between the two groups at 18 months post-operatively, measured with magnetic resonance imaging. | 18 months | — |
| Comparison of development of fatty degeneration in the supraspinatus at 18 months post-operatively | 18 months | degeneration is measured with magnetic resonance imaging and classified using the Fuchs classification (grading I-IV) |
| Number of adverse events for any cause | 7 days, 45-90 days, 12-18 months | — |
| Comparison of strength in abduction and external rotation between the two groups at 1, 3, 6, 12, 18, 24 months post-operatively. | 1, 3, 6, 12, 18, 24 months | Strength will be measured with a dynamometer, using International System metrics. |
Countries
Italy
Outcome results
None listed